Biomarker Predictors for Immunotherapy Benefit in Breast: Beyond PD-L1

[1] Jiang Y(2015)T-cell exhaustion in the tumor microenvironment Cell Death Dis 6 e1792-452

[2] Li Y(2018)Regulation and Function of the PD-L1 Checkpoint Immunity 48 434-e24306

[3] Zhu B(2018)Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors Journal of Clinical Oncology 36 e24306-2201

[4] Sun C(2011)Overall survival and PD-L1 expression in metastasized malignant melanoma Cancer 117 2192-10

[5] Mezzadra R(2018)PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer Mol Diagn Ther 22 1-686

[6] Schumacher TN(2018)Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study Breast Cancer Res Treat 167 671-2121

[7] Oyan Basak(2018)Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer N Engl J Med 379 2108-896

[8] Sonmez Ozlem(2018)Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance Histopathology 73 887-57133

[9] Yazar Aziz(2017)Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity Oncotarget 8 57121-34

[10] Teomete Mehmet(2017)Adaptive immunity programmes in breast cancer Immunology 150 25-616

[1] Jiang Y(2015)T-cell exhaustion in the tumor microenvironment Cell Death Dis 6 e1792-452

[2] Li Y(2018)Regulation and Function of the PD-L1 Checkpoint Immunity 48 434-e24306

[3] Zhu B(2018)Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors Journal of Clinical Oncology 36 e24306-2201

[4] Sun C(2011)Overall survival and PD-L1 expression in metastasized malignant melanoma Cancer 117 2192-10

[5] Mezzadra R(2018)PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer Mol Diagn Ther 22 1-686

[6] Schumacher TN(2018)Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study Breast Cancer Res Treat 167 671-2121

[7] Oyan Basak(2018)Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer N Engl J Med 379 2108-896

[8] Sonmez Ozlem(2018)Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance Histopathology 73 887-57133

[9] Yazar Aziz(2017)Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity Oncotarget 8 57121-34

[10] Teomete Mehmet(2017)Adaptive immunity programmes in breast cancer Immunology 150 25-616